Pulse Biosciences, Inc. (PLSE)
Pre-market:
| Previous close | 12.20 |
| Open | 11.97 |
| Bid | 12.00 x 200 |
| Ask | 12.18 x 100 |
| Day's range | 11.60 - 12.40 |
| 52-week range | 3.78 - 14.96 |
| Volume | |
| Avg. volume | 216,407 |
| Market cap | 675.624M |
| Beta (5Y monthly) | 1.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
HAYWARD, Calif., May 20, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has determined a new record date for the Company’s previously announced rights offering (the "Rights Offering"), which will be available to all holders of record of the Company’s common stock, par value $0.001 per share (the "Common Stock
- Business Wire
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
HAYWARD, Calif., May 16, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.
- Business Wire
Pulse Biosciences Enhances Executive Leadership Team
HAYWARD, Calif., May 14, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology ("Pulse"), today announced enhancements to its executive leadership team to support its next pivotal phase of growth.
